Kevin Sanders is currently based in Basel, Switzerland, where he has worked for Roche for the past two years. He is the Global Lead for the Autism Program for Roche Product Development.
Before Roche, he was an associate clinical professor of psychiatry and the director of the Child and Adolescent Psychiatry Division at Vanderbilt University. He also served as the director of the Child Psychiatry Consult Service at Vanderbilt Children’s Hospital, attending inpatient physician at the Vanderbilt Psychiatry Hospital, co-site principal investigator of the Autism Treatment Network, director of the Medical Exploration of Neurodevelopmental Disorders (MEND) research program and medical director of the Treatment and Research Institute for Autism Spectrum Disorders (TRIAD) at Vanderbilt Kennedy Center.
He has had extensive experience in clinical research in autism, including participation either as a principal investigator or sub-investigator in most trials for new molecular entities targeting autism, including arbaclofen, mavoglurant, basimglurant and memantine. He was also the site principal investigator for federally sponsored metformin and oxytocin trials for autism conducted at Vanderbilt University.
Sanders did his medical training at the University of Tennessee College of Medicine, his residency in psychiatry at the University of North Carolina at Chapel Hill and completed his child and adolescent psychiatry fellowship at Duke University, where he served as the chief fellow. He is board certified in general psychiatry and child and adolescent psychiatry.